Evidence map›Paper›PMID 39235679›Full record

ArticleDiscover oncology2024

The role of KLF5 in gut microbiota and lung adenocarcinoma: unveiling programmed cell death pathways and prognostic biomarkers.

Qingliang Fang, Meijun Xu, Wenyi Yao, Ruixin Wu, Ruiqin Han, Satoru Kawakita, Aidan Shen, Sisi Guan, Jiliang Zhang, Xiuqiao Sun and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qingliang Fang *Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China.
Meijun Xu *Acupuncture and Moxibustion Department, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, Jiangxi Province, China.
Wenyi Yao *Department of Oncology II, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
Ruixin WuPreclinical Department, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No.274, Zhijiang Road, Jing'an District, Shanghai, 200071, China.
Ruiqin HanState Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.
Satoru KawakitaTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Aidan ShenTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Sisi GuanLonghua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China.
Jiliang ZhangBeijing Tong Ren Tang Chinese Medicine Co., LTD, Hong Kong, 999077, China.
Xiuqiao SunLonghua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China.
Mingxi ZhouLonghua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China.
Ning LiPreclinical Department, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, No.274, Zhijiang Road, Jing'an District, Shanghai, 200071, China.
Qiaoli SunLonghua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China. sunny5sunny@163.com.
Chang-Sheng DongLonghua Hospital, Shanghai University of Traditional Chinese Medicine, No.725, Wanping Rd, Shanghai, 200032, China. csdong@shutcm.edu.cn.

Funding

Xinglin Youth Talent Training System of Shanghai University of Traditional Chinese Medicine Xinglin Young Scholars RC-2017-02-02
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most important subtype of lung cancer. It is well known that the gut microbiome plays an important role in the pathophysiology of various diseases, including cancer, but little research has been done on the intestinal microbiome associated with LUAD. Utilizing bioinformatics tools and data analysis, we identified novel potential prognostic biomarkers for LUAD. To integrate differentially expressed genes and clinical significance modules, we used a weighted correlation network analysis system. According to the Peryton database and the gutMGene database, the composition and structure of gut microbiota in LUAD patients differed from those in healthy individuals. LUAD was associated with 150 gut microbiota and 767 gut microbiota targets, with Krüppel-like factor 5 (KLF5) being the most closely related. KLF5 was associated with immune status and correlated well with the prognosis of LUAD patients. The identification of KLF5 as a potential prognostic biomarker suggests its utility in improving risk stratification and guiding personalized treatment strategies for LUAD patients. Altogether, KLF5 could be a potential prognostic biomarker in LUAD.

Indexed as

BiomarkersGut microbiotaIntestinal mucosal-related cancerKLF5Lung adenocarcinoma

Identifiers

PMID39235679
PMCPMC11377401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.